젠맵(GMAB)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $34.93 (+1.14%), 시가총액 $16.71B, PER (주가수익비율) 20.77, 52주 최저~최고 $20.30 ~ $35.34.
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab
젠맵의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
젠맵의 현재 주가는 $34.93 (+1.14%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
젠맵의 시가총액은 약 $16.71B입니다. PER은 20.77입니다.
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adu